Bio Green Med Solution, INC. (BGMSP) — 10-Q Filings

10-Q Filings (6)

• BGMSP Pivots to Fire Safety, Reports $5M Deconsolidation Gain — Nov 13, 2025 Risk: high
  Bio Green Med Solution, Inc. (BGMSP) underwent a significant strategic shift in 2025, transitioning from a biopharmaceutical company to a diversified entity foc
• Cyclacel Narrows Loss Amid Strategic Pivot, Proposed Merger — Aug 14, 2025 Risk: high
  Cyclacel Pharmaceuticals, Inc. reported a net loss of $1.399 million for the six months ended June 30, 2025, a significant improvement from the $6.203 million n
• Cyclacel Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: low
  Cyclacel Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Xcyte Therapies Inc., is incorpor
• Cyclacel Pharmaceuticals Reports Q3 2024 Results — Nov 12, 2024 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss for the period. Key financial data inclu
• Cyclacel Pharmaceuticals Q2 2024 Update — Aug 14, 2024 Risk: medium
  Cyclacel Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $1.5 million. The filing al
• Cyclacel Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Cyclacel Pharmaceuticals, Inc. filed a 10-Q report for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX